DK0580860T4 - Fremgangsmåde til fremstilling af en fast dispersion - Google Patents

Fremgangsmåde til fremstilling af en fast dispersion

Info

Publication number
DK0580860T4
DK0580860T4 DK92907654T DK92907654T DK0580860T4 DK 0580860 T4 DK0580860 T4 DK 0580860T4 DK 92907654 T DK92907654 T DK 92907654T DK 92907654 T DK92907654 T DK 92907654T DK 0580860 T4 DK0580860 T4 DK 0580860T4
Authority
DK
Denmark
Prior art keywords
solid dispersion
preparing
chemicals
twin
dissolving
Prior art date
Application number
DK92907654T
Other languages
Danish (da)
English (en)
Other versions
DK0580860T3 (da
Inventor
Kouichi Nakamichi
Shougo Izumi
Hiroyuki Yasuura
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14589572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0580860(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of DK0580860T3 publication Critical patent/DK0580860T3/da
Application granted granted Critical
Publication of DK0580860T4 publication Critical patent/DK0580860T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DK92907654T 1991-04-16 1992-04-14 Fremgangsmåde til fremstilling af en fast dispersion DK0580860T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11255491 1991-04-16
PCT/JP1992/000470 WO1992018106A1 (en) 1991-04-16 1992-04-14 Method of manufacturing solid dispersion

Publications (2)

Publication Number Publication Date
DK0580860T3 DK0580860T3 (da) 1998-05-25
DK0580860T4 true DK0580860T4 (da) 2005-03-21

Family

ID=14589572

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907654T DK0580860T4 (da) 1991-04-16 1992-04-14 Fremgangsmåde til fremstilling af en fast dispersion

Country Status (12)

Country Link
US (1) US5456923A (ko)
EP (1) EP0580860B2 (ko)
JP (1) JP2527107B2 (ko)
KR (1) KR0182801B1 (ko)
AT (1) ATE159426T1 (ko)
AU (1) AU1537292A (ko)
CA (1) CA2108575C (ko)
DE (1) DE69222847T3 (ko)
DK (1) DK0580860T4 (ko)
ES (1) ES2111065T5 (ko)
GR (1) GR3025864T3 (ko)
WO (1) WO1992018106A1 (ko)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ES2109377T3 (es) 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
KR100291361B1 (ko) * 1992-10-14 2001-09-17 니뽄 신야쿠 가부시키가이샤 결정상태의전이방법
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5700410A (en) * 1992-10-16 1997-12-23 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
WO1995005809A1 (fr) * 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation
GB2281697A (en) 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US5688510A (en) * 1993-11-18 1997-11-18 Nippon Shinyaku Co. Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
EP0797987B1 (en) * 1994-12-19 2003-10-15 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparation and process for producing the same
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EE03902B1 (et) * 1996-05-20 2002-12-16 Janssen Pharmaceutica N.V. Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
JPH10114682A (ja) * 1996-10-11 1998-05-06 Shimizu Kagaku Kk グルコマンナン配合持効性内服用薬剤
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO1999034780A1 (de) * 1998-01-12 1999-07-15 Bühler AG Verfahren und vorrichtung zum verkapseln von wirkstoffen
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
DE29923848U1 (de) * 1998-05-27 2001-04-12 Euroceltique S.A., Luxemburg/Luxembourg Präparate zur Anwendung von entzündungshemmenden, insbesondere antiseptischen Wirkstoffen und/oder die Wundheilung fördernden Wirkstoffen in den oberen Atemwegen und/oder dem Ohr
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
DE19842914A1 (de) * 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
US6350786B1 (en) † 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
DK1140026T3 (da) * 1998-12-16 2006-01-02 Aventis Pharma Inc Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
RU2264827C2 (ru) 1999-05-27 2005-11-27 Еуро-Селтик С.А. Препараты для введения противовоспалительных агентов
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
DE19949897A1 (de) * 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
EP1712222A3 (en) 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
CN1193754C (zh) * 2000-03-21 2005-03-23 日本新药株式会社 释放控制型口服制剂
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
AU7105501A (en) * 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP4997683B2 (ja) * 2000-09-25 2012-08-08 日本新薬株式会社 医薬固体分散体の製法
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
ITMI20010141A1 (it) * 2001-01-26 2002-07-26 Giuliani Spa Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
ATE307571T1 (de) * 2001-02-27 2005-11-15 Pharmazeutische formulierung enthaltend bicalutamid
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
SK15732003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
MXPA03011922A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
BR0313428A (pt) 2002-08-12 2005-06-28 Pfizer Prod Inc Composições farmacêuticas de drogas semi-ordenados e polìmeros
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1592760A4 (en) * 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
CN101091695B (zh) * 2003-02-03 2011-01-19 诺瓦提斯公司 药物制剂
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
KR20060096076A (ko) * 2003-11-14 2006-09-05 화이자 프로덕츠 인크. 비만 치료를 위한 ｍｔｐ 저해제의 고형 무정형 분산물
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
EA010369B1 (ru) 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
US20050238721A1 (en) * 2004-04-07 2005-10-27 Acquarulo Lawrence A Jr One step compounding extrusion of drug filled polymers
US20070237823A1 (en) * 2004-05-04 2007-10-11 Thomas Bock Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
EP1753766A1 (en) 2004-05-25 2007-02-21 Pfizer Products Inc. Tetraazabenzo(e)azulene derivatives and analogs thereof
EP1753402B1 (en) * 2004-05-28 2008-10-01 Pfizer Products Incorporated Pharmaceutical compositions with enhanced performance comprising a hpmca polymer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
EP2548894A1 (en) 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
EP1912621B1 (de) * 2005-08-02 2019-09-11 Drossapharm AG Pharmazeutische zusammensetzung enthaltend indometacin und/oder acemetacin
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US7607596B1 (en) 2007-03-07 2009-10-27 Exxpharma, LLC Process for enhancing the solubility of poorly soluble drugs
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
CA3076115C (en) * 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2009038112A1 (ja) * 2007-09-21 2009-03-26 Shionogi & Co., Ltd. Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
DK2200588T3 (da) * 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
FR2922100B1 (fr) * 2007-10-11 2009-12-11 Oreal Procede de preparation de particules semi-solides a interet cosmetique
WO2009053635A1 (fr) * 2007-10-11 2009-04-30 L'oreal Composition cosmetique structuree
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719507C (en) * 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
ES2559029T3 (es) 2009-04-24 2016-02-10 Tissue Tech, Inc. Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
PT2442791T (pt) 2009-06-16 2020-02-06 Pfizer Formas farmacêuticas de apixaban
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
PE20121327A1 (es) 2009-11-06 2012-10-18 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
US20110236465A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Melt-extruded film
US20110236666A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Melt-extruded film
US20110236443A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Multilayer melt-extruded film
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
PL2563776T3 (pl) 2010-04-27 2017-01-31 Calcimedica Inc Związki, które modulują wewnątrzkomórkowy wapń
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012003350A1 (en) 2010-07-02 2012-01-05 The Procter & Gamble Company Methods of delivering a health care active by administering personal health care articles comprising a filament
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
KR20140006879A (ko) 2011-02-17 2014-01-16 에프. 호프만-라 로슈 아게 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
DE102011015370A1 (de) * 2011-03-29 2012-10-04 Emodys Gmbh Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN107982266B (zh) 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
EP2822539B1 (en) 2012-03-07 2018-11-21 National Institute Of Pharmaceutical Education And Research (NIPER) Nanocrystalline solid dispersion compositions
MD20140103A2 (ro) 2012-04-06 2015-01-31 Pfizer Inc. Inhibitori ai diacilglicerol aciltransferazei 2
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
CA2878163A1 (en) 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102191562B1 (ko) 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
CA2891502A1 (en) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
JP6150518B2 (ja) 2012-12-27 2017-06-21 花王株式会社 ポリフェノール組成物の製造方法
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US9296882B2 (en) 2013-09-04 2016-03-29 Zzyzx Polymers LLC Methods for increasing throughput rates of solid-state extrusion devices
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20150104508A1 (en) * 2013-10-12 2015-04-16 Zzyzx Polymers LLC Devices, compositions, and methods for fabricating drug delivery systems
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
JP6933465B2 (ja) 2013-12-31 2021-09-08 アセンディア ファーマシューティカルズ，エルエルシー 難水溶性化合物のための医薬組成物
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
HUE039446T2 (hu) 2014-03-17 2018-12-28 Pfizer Diacilglicerol-aciltranszferáz-2 inhibitorok metabolikus rendellenességek és kapcsolódó rendellenességek kezelésében történõ alkalmazásra
WO2015141662A1 (ja) * 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016031651A1 (ja) 2014-08-29 2016-03-03 花王株式会社 難溶解性ポリフェノール類を含有する固体分散体の製造方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
CA2964068A1 (en) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Methods of preparing extrudates
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA2974395C (en) 2015-02-06 2023-08-22 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
CN107427462B (zh) * 2015-03-12 2023-08-29 杜邦营养美国有限公司 固态分散体
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
JP2018516869A (ja) 2015-05-20 2018-06-28 ティッシュテック，インク． 上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
CN107847437B (zh) 2015-05-28 2024-03-26 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN108135904A (zh) 2015-08-31 2018-06-08 药品循环有限责任公司 用于治疗多发性骨髓瘤的btk抑制剂组合
WO2017100861A1 (en) 2015-12-16 2017-06-22 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
CN108472259A (zh) 2016-01-19 2018-08-31 詹森药业有限公司 包含btk抑制剂的配制品/组合物
WO2017125424A1 (en) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017176652A2 (en) 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
JP2019516700A (ja) 2016-05-12 2019-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
BR112018071740A2 (pt) 2016-05-13 2019-02-19 Merck Patent Gmbh tamanho de partícula e distribuição de polímero para aplicação de extrusão por fusão
JP7000348B2 (ja) 2016-05-13 2022-01-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 可塑剤としてのアミノ糖の使用
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CA3030821A1 (en) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
AU2017314842B9 (en) 2016-08-26 2022-02-10 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
CA3042770A1 (en) 2016-11-07 2018-05-11 Merck Patent Gmbh Anti-alcohol-induced dose dumping tablet based on polyvinyl alcohol
BR112019009159A2 (pt) 2016-11-07 2019-07-16 Merck Patent Gmbh comprimido de liberação controlada à base de álcool de polivinila e sua produção
KR20190083653A (ko) 2016-11-07 2019-07-12 메르크 파텐트 게엠베하 고온 용융 압출된 폴리비닐 알코올에 기반하는 즉각 방출 캡슐
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
MX2019010756A (es) 2017-03-10 2020-01-20 Pfizer Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
CN109320428A (zh) * 2017-08-01 2019-02-12 浙江普利药业有限公司 一种马来酸曲美布汀晶型及其制备方法
WO2019046731A1 (en) 2017-09-01 2019-03-07 University Of Washington CRYSTALLINE FORMS OF COMPOUNDS FOR PREVENTING OR TREATING DEATH OF SENSORY CILIC CELLS
US11382897B2 (en) 2017-11-07 2022-07-12 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
US10632209B2 (en) 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
JP7414282B2 (ja) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｎｓｄファミリー阻害物質及びそれによる治療の方法
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
JP2021532183A (ja) 2018-07-27 2021-11-25 コンセントリック アナルジェジクス，インク． フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020046466A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
CR20210110A (es) 2018-08-31 2021-05-13 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
KR20210117261A (ko) 2018-12-31 2021-09-28 바이오메아 퓨전, 인크. 메닌-mll 상호작용의 비가역적 억제제
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
CA3133093A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics, Inc. Nicorandil derivatives
US20220175677A1 (en) * 2019-04-08 2022-06-09 Cosci Med-Tech Co., Ltd. Methods of improving pharmaceutical substance solubilization and products thereof
KR20220003565A (ko) 2019-04-19 2022-01-10 화이자 인코포레이티드 Pah를 치료하기 위한 항증식제
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
CA3218884A1 (en) 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions
EP4346788A2 (en) 2021-06-03 2024-04-10 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2023028091A1 (en) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Deuterated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
CR20240183A (es) 2021-12-01 2024-06-07 Pfizer Inhibidores y/o degradadores de bckdk
EP4444708A1 (en) 2021-12-06 2024-10-16 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024011142A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257315A (en) * 1975-11-04 1977-05-11 Sandoz Ag Tablet for medical preparation
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS58109411A (ja) * 1981-12-23 1983-06-29 Shionogi & Co Ltd ニフエジピン固型製剤組成物
JPS6240277A (ja) * 1985-08-15 1987-02-21 Ajinomoto Co Inc 顆粒状食品の製造法
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US4760094A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4842761A (en) * 1988-03-23 1989-06-27 International Flavors & Fragrances, Inc. Compositions and methods for controlled release of fragrance-bearing substances
DE3812567A1 (de) † 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3827061C1 (ko) * 1988-08-10 1990-02-15 Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
NZ231281A (en) * 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
FR2670398B1 (fr) * 1990-12-14 1995-02-17 Roquette Freres Composition pulverulente directement compressible et procede d'obtention.
ES2109377T3 (es) * 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
US5700410A (en) * 1992-10-16 1997-12-23 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
DE69530670T2 (de) * 1994-09-21 2004-03-18 Kanegafuchi Kagaku Kogyo K.K. Verfahren zur absorption von interleukine
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US5954175A (en) * 1997-09-02 1999-09-21 Northrop Grumman Corporation Modularized parallel drivetrain
AU9587198A (en) * 1997-10-07 1999-04-27 Fuisz Technologies Ltd. Immediate release drug delivery forms
US6029764A (en) * 1997-11-12 2000-02-29 Case Corporation Coordinated control of an active suspension system for a work vehicle
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs

Also Published As

Publication number Publication date
US5456923A (en) 1995-10-10
CA2108575A1 (en) 1992-10-17
ATE159426T1 (de) 1997-11-15
DK0580860T3 (da) 1998-05-25
JP2527107B2 (ja) 1996-08-21
CA2108575C (en) 2002-10-22
EP0580860B2 (en) 2004-12-15
DE69222847D1 (de) 1997-11-27
ES2111065T5 (es) 2005-06-16
AU1537292A (en) 1992-11-17
ES2111065T3 (es) 1998-03-01
GR3025864T3 (en) 1998-04-30
DE69222847T2 (de) 1998-05-20
EP0580860A1 (en) 1994-02-02
KR0182801B1 (ko) 1999-05-01
WO1992018106A1 (en) 1992-10-29
EP0580860B1 (en) 1997-10-22
DE69222847T3 (de) 2005-09-15
EP0580860A4 (en) 1994-06-15

Similar Documents

Publication Publication Date Title
DK0580860T4 (da) Fremgangsmåde til fremstilling af en fast dispersion
BR8902877A (pt) Processo para a producao de compostos estabilizantes uv para polimeros organicos
DK0828601T3 (da) Fremgangsmåde til fremstilling af rørformede, varmegenoprettelige genstande
BR9006937A (pt) Processo de extrusao para polimeros dificilmente processaveis por fusao
Liu et al. Solvent vapor annealing: An efficient approach for inscribing secondary nanostructures onto electrospun fibers
DK0565184T3 (da) Fremgangsmåde til opnåelse af granulære former af additiver til organiske polymerer
ATE156165T1 (de) Ölabstossende polymerzusammensetzungen und ihre verwendung zur herstellung von geformten körpern, die mit hoher lösungsmittelstabilität und geringer verschmutzungsneigung ausgestattet sind
FR2306227A1 (fr) Procede de fabrication de copolyesters sequences a viscosite de fusion elevee
DE3750263D1 (de) Vernetzte polypropylenfasern, verfahren zur herstellung und nichtgewobene textilien daraus.
NL183295C (nl) Werkwijze voor het stabiliseren van organische polymeren, voor de bereiding van daarvoor geschikte verbindingen.
ATE128998T1 (de) Härtbare zusammensetzung, die ein kristallisierbares polymer enthält.
DE3786689D1 (de) Optisches kunststoff-transmissionsmedium, zugehoeriges herstellungsverfahren und linsenanordnung mit solchem medium.
BR8902059A (pt) Processo para preparacao de composicao termoplastica,composicao termoplastica e dispositivo para preparacao de composicao termoplastica
DK1062104T4 (da) Fremgangsmåde til fremstilling af et sikkerhedselement
WO1991015526A3 (en) Thermoreversible heat-thickening polyacrylamides
DE68927776D1 (de) Verfahren zur Herstellung von statistischen Cycloolefincopolymeren
DE69213559D1 (de) Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff
FI924528A (fi) Liukukappale vetoketjua varten ja sen valmistusmenetelmä
DE3861789D1 (de) Verbundstoffe mit schmierender wirkung, verfahren zu deren herstellung und anti-erodierende elemente fuer rohrwaffen, die aus diesen materialien hergestellt sind.
ATE252407T1 (de) Schwimmbrille und verfahren zu deren herstellung
FR2768741B1 (fr) Procede de fabrication de polyamides
DE68921648D1 (de) Supraleiter und Verfahren zu deren Herstellung.
ATE322739T1 (de) Serien herstellungsverfahren von sicherungshaltermodule und sicherungshaltermodule hergestellt mit diesem verfahren
DK0550115T3 (da) Fremgangsmåde til fremstilling af en porøs film med en høj brudstyrke
DE69934021D1 (de) Herstellung von polymeren mit hilfe von sternverknüpfungen